Zaynich, approved by the US Food and Drug Administration for complicated urinary tract infections and pyelonephritis, is aimed at treating infections caused by drug-resistant bacteria — an area where doctors globally are facing shrinking treatment options as antimicrobial resistance rises. This approval has handed Wockhardt a regulatory win that few Indian drugmakers have achieved. But beyond the milestone, the approval will test whether years of investment in pharmaceutical innovation can finally generate commercial returns.
The drug's approval is notable because it is the first New Chemical Entity (NCE) discovered and developed in India to receive US FDA clearance, a distinction that highlights the rarity of successful drug discovery programmes emerging from the country's pharmaceutical sector.
A Bet on Innovation
For much of the past decade, Wockhardt has been attempting to move away from a business model dependent on generic medicines, a segment characterised by intense competition and pricing pressure.
Instead, the company has spent heavily on research and development, building a pipeline of proprietary medicines. That strategy has often come at a cost, with investors questioning whether the company's R&D spending would eventually translate into commercially viable products.
Zaynich now becomes the most visible test of that thesis. Clinical trial data showed the antibiotic outperformed meropenem, a widely used treatment for severe bacterial infections. According to the company, Zaynich achieved an 89% success rate compared with 68% for meropenem and was generally well tolerated by patients.
Commercial Opportunity Comes With Challenges
The approval opens access to a global antibiotic market estimated at around $9 billion. However, commercialising novel antibiotics has historically been difficult despite the urgent medical need. While antimicrobial resistance is a growing global health concern, antibiotic developers often face challenges in generating meaningful revenues because newer drugs are typically reserved for the most severe cases to avoid overuse and preserve effectiveness.
Even so, analysts see the US market as a significant opportunity, with treatment costs for advanced antibiotics often running into thousands of dollars per patient. Wockhardt has already secured approval for the drug in India and has filed for regulatory approval in Europe.
The approval also shifts attention to Wockhardt's broader pipeline. The company has several antibiotic candidates under development, including WCK 6777 and Nafithromycin, alongside a biologics portfolio focused on diabetes therapies such as insulin and GLP-1-based treatments.
Financially, Wockhardt's revenue rose to Rs 3,373 crore in FY26 from Rs 2,651 crore in FY23, while EBITDA margins expanded from 4% to 19%. The company also returned to profitability during the period.
ALSO READ: Wockhardt Shares Surge Over 11% After CDSCO Nod For Zaynich Antibiotic In India
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.